Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 5.3% Higher

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price rose 5.3% on Wednesday . The company traded as high as $7.24 and last traded at $7.12. Approximately 1,385,716 shares traded hands during trading, a decline of 76% from the average daily volume of 5,842,706 shares. The stock had previously closed at $6.76.

Analyst Ratings Changes

Several brokerages recently commented on RXRX. Leerink Partners decreased their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Tuesday, September 3rd. Jefferies Financial Group cut their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Needham & Company LLC reduced their target price on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday, September 4th. Finally, KeyCorp decreased their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $9.40.

Recursion Pharmaceuticals Stock Performance

The firm has a market capitalization of $1.97 billion, a P/E ratio of -4.44 and a beta of 0.82. The company has a 50-day simple moving average of $7.20 and a two-hundred day simple moving average of $8.43. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 6.07.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). The firm had revenue of $14.42 million during the quarter, compared to analysts’ expectations of $11.96 million. Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. Recursion Pharmaceuticals’s revenue for the quarter was up 30.9% on a year-over-year basis. During the same period in the previous year, the company earned ($0.38) earnings per share. As a group, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current year.

Insider Transactions at Recursion Pharmaceuticals

In related news, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $6.17, for a total transaction of $92,550.00. Following the completion of the transaction, the chief financial officer now directly owns 1,377,756 shares of the company’s stock, valued at approximately $8,500,754.52. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 50,000 shares of Recursion Pharmaceuticals stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $7.48, for a total value of $374,000.00. Following the completion of the sale, the chief executive officer now owns 758,738 shares of the company’s stock, valued at approximately $5,675,360.24. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $6.17, for a total value of $92,550.00. Following the completion of the sale, the chief financial officer now owns 1,377,756 shares of the company’s stock, valued at $8,500,754.52. The disclosure for this sale can be found here. Insiders have sold 231,682 shares of company stock valued at $1,663,867 in the last three months. 15.75% of the stock is currently owned by company insiders.

Institutional Trading of Recursion Pharmaceuticals

A number of hedge funds have recently bought and sold shares of RXRX. Wedmont Private Capital increased its position in shares of Recursion Pharmaceuticals by 11.8% during the 1st quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock valued at $172,000 after purchasing an additional 2,000 shares during the last quarter. Interchange Capital Partners LLC raised its position in Recursion Pharmaceuticals by 7.3% in the second quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock worth $268,000 after acquiring an additional 2,349 shares during the period. Amalgamated Bank raised its position in Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after acquiring an additional 2,459 shares during the period. Benjamin F. Edwards & Company Inc. purchased a new position in shares of Recursion Pharmaceuticals during the 1st quarter worth $26,000. Finally, Victory Capital Management Inc. grew its position in shares of Recursion Pharmaceuticals by 13.5% during the 2nd quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock valued at $164,000 after acquiring an additional 2,598 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.